Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISE trial of inhaled amikacin liposome suspension in newly diagnosed MAC lung disease
MOH_2020-12-07_009547Phase 3Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Oct 2020
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amikacin liposome in nontuberculous mycobacterial lung disease and Mycobacterium avium-intracellulare infection (MAI) (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Not reported. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
amikacin liposome
03
Conditions
nontuberculous mycobacterial lung diseaseMycobacterium avium-intracellulare infection (MAI)
Beyond the preview
Go deeper on MOH_2020-12-07_009547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-07_009547.